改革开放15年来,我国医药进出口贸易日趋活跃,年总额已达25亿美元,其中进口10亿美元,对弥补国内生产之不足,保证市场供应起到了积极作用。但也存在着多头管理、进口渠道混乱、结构不合理等一系列问题,严重影响着民族工业的发展。加之,我国即将恢复关税及贸易总协定缔约国地位,多年来进口实行的高关税、许可证制度(1991年药品进口改为注册证)、数量限制、行政审批等贸易保护措施将大大减少,随之而来的必将是进口药品的大量增加,因 In the past 15 years of reform and opening up, China’s pharmaceutical import and export trade has become increasingly active. The total annual amount has reached US$2.5 billion, of which imports of US$1 billion have played a positive role in remedying the insufficiency of domestic production and ensuring market supply. However, there are also a series of problems such as long management, chaotic import channels, and unreasonable structure, which seriously affect the development of national industries. In addition, China is about to resume the status of the State party to the General Agreement on Tariffs and Trade. Over the years, the trade protection measures such as high tariffs, permit systems (drugs imported into registration certificates), quantitative restrictions, and administrative approvals will be greatly reduced. And it will certainly be a large increase in imported medicines because